|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RHOQ |
Gene summary for RHOQ |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RHOQ | Gene ID | 23433 |
| Gene name | ras homolog family member Q | |
| Gene Alias | ARHQ | |
| Cytomap | 2p21 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P17081 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23433 | RHOQ | HCC1_Meng | Human | Liver | HCC | 1.08e-77 | 2.44e-01 | 0.0246 |
| 23433 | RHOQ | HCC2_Meng | Human | Liver | HCC | 3.38e-08 | 3.12e-02 | 0.0107 |
| 23433 | RHOQ | HCC2 | Human | Liver | HCC | 8.38e-29 | 4.32e+00 | 0.5341 |
| 23433 | RHOQ | Pt13.b | Human | Liver | HCC | 2.47e-02 | 1.31e-01 | 0.0251 |
| 23433 | RHOQ | S027 | Human | Liver | HCC | 3.46e-07 | 7.16e-01 | 0.2446 |
| 23433 | RHOQ | S028 | Human | Liver | HCC | 2.11e-12 | 6.60e-01 | 0.2503 |
| 23433 | RHOQ | S029 | Human | Liver | HCC | 2.15e-14 | 7.51e-01 | 0.2581 |
| 23433 | RHOQ | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 4.38e-06 | 6.27e-01 | -0.2247 |
| 23433 | RHOQ | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 3.87e-04 | 3.73e-01 | -0.1833 |
| 23433 | RHOQ | 047563_1562-all-cells | Human | Prostate | BPH | 8.83e-14 | 5.69e-01 | 0.0791 |
| 23433 | RHOQ | 048752_1579-all-cells | Human | Prostate | BPH | 3.52e-14 | 4.40e-01 | 0.1008 |
| 23433 | RHOQ | 052095_1628-all-cells | Human | Prostate | BPH | 4.03e-06 | 3.64e-01 | 0.1032 |
| 23433 | RHOQ | 052097_1595-all-cells | Human | Prostate | BPH | 2.82e-30 | 6.84e-01 | 0.0972 |
| 23433 | RHOQ | 052099_1652-all-cells | Human | Prostate | BPH | 1.85e-05 | 3.49e-01 | 0.1038 |
| 23433 | RHOQ | Dong_P1 | Human | Prostate | Tumor | 5.12e-14 | 7.44e-02 | 0.035 |
| 23433 | RHOQ | Dong_P3 | Human | Prostate | Tumor | 9.43e-04 | 3.77e-02 | 0.0278 |
| 23433 | RHOQ | Dong_P5 | Human | Prostate | Tumor | 2.97e-04 | -5.69e-02 | 0.053 |
| 23433 | RHOQ | Adj_PTCwithHT_6 | Human | Thyroid | HT | 5.67e-05 | -2.10e-01 | 0.02 |
| 23433 | RHOQ | PTCwithHT_6 | Human | Thyroid | HT | 1.15e-03 | -2.06e-01 | 0.02 |
| 23433 | RHOQ | PTCwithHT_8 | Human | Thyroid | HT | 5.67e-05 | -2.10e-01 | 0.0351 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190165315 | Prostate | Tumor | cellular response to peptide | 104/3246 | 359/18723 | 2.71e-08 | 8.90e-07 | 104 |
| GO:199077815 | Prostate | Tumor | protein localization to cell periphery | 97/3246 | 333/18723 | 5.88e-08 | 1.75e-06 | 97 |
| GO:000616319 | Prostate | Tumor | purine nucleotide metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
| GO:001969318 | Prostate | Tumor | ribose phosphate metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
| GO:000920517 | Prostate | Tumor | purine ribonucleoside triphosphate metabolic process | 35/3246 | 82/18723 | 6.76e-08 | 1.95e-06 | 35 |
| GO:007252119 | Prostate | Tumor | purine-containing compound metabolic process | 115/3246 | 416/18723 | 8.47e-08 | 2.31e-06 | 115 |
| GO:004343418 | Prostate | Tumor | response to peptide hormone | 113/3246 | 414/18723 | 2.24e-07 | 5.42e-06 | 113 |
| GO:000919916 | Prostate | Tumor | ribonucleoside triphosphate metabolic process | 35/3246 | 89/18723 | 7.39e-07 | 1.47e-05 | 35 |
| GO:007137514 | Prostate | Tumor | cellular response to peptide hormone stimulus | 83/3246 | 290/18723 | 1.14e-06 | 2.16e-05 | 83 |
| GO:003286915 | Prostate | Tumor | cellular response to insulin stimulus | 63/3246 | 203/18723 | 1.15e-06 | 2.18e-05 | 63 |
| GO:000836015 | Prostate | Tumor | regulation of cell shape | 51/3246 | 154/18723 | 1.42e-06 | 2.56e-05 | 51 |
| GO:000914118 | Prostate | Tumor | nucleoside triphosphate metabolic process | 40/3246 | 112/18723 | 2.30e-06 | 3.91e-05 | 40 |
| GO:003286815 | Prostate | Tumor | response to insulin | 75/3246 | 264/18723 | 4.94e-06 | 7.68e-05 | 75 |
| GO:003134614 | Prostate | Tumor | positive regulation of cell projection organization | 94/3246 | 353/18723 | 6.96e-06 | 1.05e-04 | 94 |
| GO:190547515 | Prostate | Tumor | regulation of protein localization to membrane | 54/3246 | 175/18723 | 7.84e-06 | 1.16e-04 | 54 |
| GO:190307616 | Prostate | Tumor | regulation of protein localization to plasma membrane | 36/3246 | 104/18723 | 1.61e-05 | 2.16e-04 | 36 |
| GO:000911718 | Prostate | Tumor | nucleotide metabolic process | 120/3246 | 489/18723 | 2.81e-05 | 3.41e-04 | 120 |
| GO:000675317 | Prostate | Tumor | nucleoside phosphate metabolic process | 121/3246 | 497/18723 | 3.81e-05 | 4.41e-04 | 121 |
| GO:003086515 | Prostate | Tumor | cortical cytoskeleton organization | 24/3246 | 61/18723 | 3.91e-05 | 4.52e-04 | 24 |
| GO:190437515 | Prostate | Tumor | regulation of protein localization to cell periphery | 39/3246 | 125/18723 | 1.04e-04 | 1.00e-03 | 39 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0491041 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
| hsa0491051 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
| hsa049107 | Prostate | BPH | Insulin signaling pathway | 43/1718 | 137/8465 | 1.34e-03 | 5.81e-03 | 3.60e-03 | 43 |
| hsa0491012 | Prostate | BPH | Insulin signaling pathway | 43/1718 | 137/8465 | 1.34e-03 | 5.81e-03 | 3.60e-03 | 43 |
| hsa0491022 | Prostate | Tumor | Insulin signaling pathway | 44/1791 | 137/8465 | 1.69e-03 | 7.10e-03 | 4.40e-03 | 44 |
| hsa0491032 | Prostate | Tumor | Insulin signaling pathway | 44/1791 | 137/8465 | 1.69e-03 | 7.10e-03 | 4.40e-03 | 44 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RHOQ | SNV | Missense_Mutation | rs141544914 | c.614C>T | p.Thr205Met | p.T205M | P17081 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| RHOQ | SNV | Missense_Mutation | novel | c.513N>C | p.Leu171Phe | p.L171F | P17081 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| RHOQ | SNV | Missense_Mutation | novel | c.227T>C | p.Leu76Ser | p.L76S | P17081 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RHOQ | SNV | Missense_Mutation | c.499N>G | p.Thr167Ala | p.T167A | P17081 | protein_coding | deleterious(0) | possibly_damaging(0.894) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD | |
| RHOQ | SNV | Missense_Mutation | c.205N>T | p.Asp69Tyr | p.D69Y | P17081 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| RHOQ | SNV | Missense_Mutation | c.169N>C | p.Tyr57His | p.Y57H | P17081 | protein_coding | tolerated(0.27) | possibly_damaging(0.816) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RHOQ | SNV | Missense_Mutation | c.304N>A | p.Glu102Lys | p.E102K | P17081 | protein_coding | tolerated(1) | probably_damaging(0.988) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| RHOQ | SNV | Missense_Mutation | novel | c.28N>T | p.Leu10Phe | p.L10F | P17081 | protein_coding | deleterious(0) | benign(0.003) | TCGA-AX-A3G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RHOQ | SNV | Missense_Mutation | novel | c.38N>C | p.Val13Ala | p.V13A | P17081 | protein_coding | deleterious(0.01) | benign(0.031) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| RHOQ | SNV | Missense_Mutation | rs371750832 | c.196N>A | p.Gly66Arg | p.G66R | P17081 | protein_coding | deleterious(0) | benign(0.2) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |